Roche’s Tecentriq chalks up another FDA approval, this time in first-line extensive-stage small cell lung cancer
March 20, 2019Research and Development, Sales and Marketing FDA, Roche, lung cancer, pharma, tecentriq
Roche has secured another US approval for its immunotherapy Tecentriq (atezolizumab), as the FDA reveals its approval of the drug …
FDA puts multiple myeloma trial on hold after patient deaths
March 20, 2019Research and Development AbbVie, FDA, Roche, clinical trials, multiple myeloma
The FDA has placed a partial clinical hold on studies of multiple myeloma treatment Venclexta/Venclyxto (venetoclax) following a number of …
FDA approves first-ever postpartum depression therapy: Sage Therapeutics’ Zulresso
March 20, 2019Research and Development, Sales and Marketing FDA, Sage Therapeutics, depression, pharma, postpartum depression
The FDA has announced its decision to approve Sage Therapeutics’ intraveneous injection Zulresso (brexanolone), marking the first authorisation of a …
Pfizer and Merck discontinue Phase 3 avelumab ovarian cancer trial
March 20, 2019Research and Development Merck KGaA, Pfizer, javelin, oncology, ovarian cancer
Pfizer and Merck KGaA have chosen to discontinue the Phase 3 JAVELIN trial looking into avelumab in combination with chemotherapy …
Dame Sally Davies says medicinal cannabis legalisation has opened Pandora’s Box
March 20, 2019Research and Development
England’s Chief Medical Officer (CMO), Dame Sally Davies has said the legalisation of medicinal cannabis has “opened a Pandora’s Box,” …
Breast cancer mortality rates fall faster in Britain than elsewhere in Europe
March 19, 2019Manufacturing and Production, Research and Development Cancer, EU, Europe, France, Italy, Poland, UK, breast cancer, german, oncology
Death rates from breast cancer are falling faster in Britain than in any of the other six most populous countries …
AZ’s Farxiga reduces major adverse cardiovascular event risk in type 2 diabetes, new data shows
March 19, 2019Manufacturing and Production, Research and Development AstraZeneca, cardiovascular, farxiga, pharma
AstraZeneca has lifted the curtain on new Phase 3 data for its sodium-glucose co-transporter 2 (SGLT2) inhibitor Farxiga (dapagliflozin), reinforcing …
Shortage of cancer doctors puts NHS patients at risk
March 19, 2019Manufacturing and Production, Research and Development Cancer, NHS, oncologists, radiology, shortfall, staff
A shortage of cancer doctors is putting patients at risk, according to a new report from the Royal College of …
FDA approves first paediatric treatment for intra-abdominal and urinary tract infections in over 10 years
March 19, 2019Manufacturing and Production, Sales and Marketing Allergan, Avycaz, FDA, pharma
Allergan has revealed that Avycaz (ceftazidime and avibactam) has been awarded an expansion of its label by the FDA to include …
Daiichi Sankyo show positive results for atrial fibrillation treatment Lixiana
March 18, 2019Manufacturing and Production, Research and Development Daiichi Sankyo, Lixiana, pharma, vitamin K antagonist
Japanese firm Daiichi Sankyo has announced positive results of the first randomised controlled trial of uninterrupted Lixiana (edoxoban) in atrial …
Patient Experience: Living with two rare diseases
March 18, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Wyburn-Mason Syndrome, acromegaly, feature, patient experience, pharma, rare disease
Dan Jeffries was diagnosed with the ultra-rare condition Wyburn-Mason syndrome at a young age, leaving him blind in one eye. …
Allergy Therapeutics’ adjuvanted birch allergoid drug shocks with Phase 3 failure
March 18, 2019Research and Development, Sales and Marketing allergy, allergy therapeutics, pharma, trial failure
UK-based biotech firm Allergy Therapeutics has been left disappointed after it became evident that its adjuvanted birch allergoid product failed …
NHS struggles to meet targets as more demand for services grows
March 18, 2019Sales and Marketing A&E, NHS, hospitals
The NHS is struggling to meet targets as the health service is being used by more patients than ever before, …
NICE to set out new opioid prescription guidelines for GPs
March 18, 2019Sales and Marketing GPs, NICE, addiction, addictive drugs, opioids, prescription drugs, withdrawal
NICE is set to develop new guidelines for GPs and healthcare professionals setting out rules for doctors regarding opioids and …
Sanofi and Regeneron’s Praluent approved in Europe to reduce CV risk
March 18, 2019Research and Development, Sales and Marketing Regeneron, Sanofi, cardiovascular, heart, praluent
Sanofi and Regeneron’s Praluent (alirocumab) has been awarded approval by the European Commission, it has emerged, as a therapy to …
Purdue Pharma vow not to profit from fast tracked opioid overdose antidote
March 18, 2019Sales and Marketing FDA, OxyContin, Purdue Pharma, nalmefene hydrochloride, opioids
The FDA has granted OxyContin drugmaker Purdue Pharma, fast track designation for opioid overdose antidote nalmefene hydrochloride (HCl) injection. However, …
Merck KGaA enters drug discovery partnership with AI firm Itkos
March 15, 2019Medical Communications, Research and Development AI, Merck, Merck KGaA, drug discovery, pharma
Merck KGaA and artificial intelligence (AI) firm Iktos have entered into a partnership, the pair have announced, to leverage the …
National Cancer Institute Director Ned Sharpless to become interim FDA Commissioner
March 15, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Following the surprise resignation of current FDA Commissioner Dr Scott Gottlieb a week earlier, Dr Norman ‘Ned’ Sharpless, Director of …
Sandoz CEO Richard Francis to step down
March 15, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Richard Francis is set to step down his role as Chief Executive of Novartis’ generics arm Sandoz after five years’ …
Roche scores two EU approvals in haemophilia and rare autoimmune disease
March 15, 2019Medical Communications EC, EU, Europe, Roche, haemophilia, rare diseases
The European Commission (EC) has approved Roche’s haemophilia treatment Hemlibra (emicizumab). The approval comes as the EC approved Roche’s MabThera …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
